Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.38 is 104% above its 5-year average of 0.19, near the high end of its 5-year range (-0.05–0.42).
As of the fiscal period ended Wednesday, December 31, 2025. 20.63% above its 12-month average of 0.32.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.16.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 35 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:12:49.594Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.38
EARNINGS PER SHARE (EPS) AVG TTM
0.32
EARNINGS PER SHARE (EPS) AVG 3Y
0.19
EARNINGS PER SHARE (EPS) AVG 5Y
0.19
EARNINGS PER SHARE (EPS) AVG 10Y
0.18
EARNINGS PER SHARE (EPS) AVG 15Y
0.05
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+20.63%
CURRENT VS 3Y AVG
+103.15%
CURRENT VS 5Y AVG
+103.86%
CURRENT VS 10Y AVG
+116.76%
CURRENT VS 15Y AVG
+608.29%
CURRENT VS 20Y AVG
N/A
Market Cap
$450.46M
Earnings Per Share (EPS)
-0.72
TTM Avg
-0.65
3Y Avg
-0.60
5Y Avg
-0.64
Market Cap
$448.58M
Earnings Per Share (EPS)
-2.45
TTM Avg
-1.70
3Y Avg
-1.35
5Y Avg
-1.20
Market Cap
$478.35M
Earnings Per Share (EPS)
-1.99
TTM Avg
-0.88
3Y Avg
-1.91
5Y Avg
-1.95
Market Cap
$447.10M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.30
3Y Avg
-0.53
5Y Avg
-0.29
Market Cap
$476.61M
Earnings Per Share (EPS)
-0.04
TTM Avg
-0.10
3Y Avg
-0.16
5Y Avg
-0.22
Market Cap
$475.16M
Earnings Per Share (EPS)
-1.73
TTM Avg
-1.90
3Y Avg
-1.16
5Y Avg
-1.16
Market Cap
$477.46M
Earnings Per Share (EPS)
0.16
TTM Avg
-2.02
3Y Avg
-3.99
5Y Avg
-3.80
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kamada Ltd. (KMDA) | $460.98M | 0.38 | 0.32 | 0.19 | 0.19 |
| NRC Health (NRC)vs › | $461.44M | 0.25 | 0.79 | 1.03 | 1.18 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $450.46M | -0.72 | -0.65 | -0.60 | -0.64 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $448.58M | -2.45 | -1.70 | -1.35 | -1.20 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $478.35M | -1.99 | -0.88 | -1.91 | -1.95 |
| Ovid Therapeutics Inc. (OVID)vs › | $447.10M | -0.48 | -0.30 | -0.53 | -0.29 |
| Cerus Corporation (CERS)vs › | $476.61M | -0.04 | -0.10 | -0.16 | -0.22 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.16M | -1.73 | -1.90 | -1.16 | -1.16 |
| Arvinas, Inc. (ARVN)vs › | $477.46M | 0.16 | -2.02 | -3.99 | -3.80 |
| NeuroPace, Inc. (NPCE)vs › | $441.17M | -0.57 | -0.80 | -1.19 | -1.52 |
Trailing EPS (TTM)
$0.38
Forward EPS (Est.)
$0.48
P/E Ratio
21.1
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 0.38 |
| 2024-12-31 | 0.25 |
| 2023-12-31 | 0.17 |
| 2022-12-31 | -0.05 |
| 2021-12-31 | -0.05 |
| 2020-12-31 | 0.42 |
| 2019-12-31 | 0.57 |
| 2018-12-31 | 0.55 |
| 2017-12-31 | 0.18 |
| 2016-12-31 | -0.18 |
| 2015-12-31 | -0.31 |
| 2014-12-31 | -0.35 |
| 2013-12-31 | 0.01 |
| 2012-12-31 | 0.01 |
| 2011-12-31 | -0.13 |
| 2010-12-31 | -0.61 |
| 2009-12-31 | -0.88 |
| 2008-12-31 | -0.94 |
| 2007-12-31 | -2.16 |
(FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown Quote observation: 2026-10-06T15:12:49.594Z. Historical observations retain their original dates. Historical series through 2020-02-26.
